Genetic code expansion (GCE) technology enables the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins, thereby expanding the natural amino acid repertoire to introduce novel chemical and functional properties. ncAA-incorporated cytokine engineering applies this precision to redesign cytokine therapeutics with the goal of enhancing stability, activity, and selectivity while potentially reducing immunogenicity. Supported by a proprietary GCEngine platform, integrated services are offered that combine the development of orthogonal aaRS/tRNA pairs with functional validation, delivering tailored solutions for next-generation cytokine-based therapies.
Overview of ncAA Incorporated Cytokine Engineering
Cytokines are potent signaling molecules with significant therapeutic potential, yet their application is often limited by challenges such as short half-life, pleiotropic effects, and systemic toxicity. Through site-specific ncAA incorporation, cytokine structures can be precisely modified to improve pharmacokinetic profiles, enhance target engagement, enable site-specific conjugation for half-life extension or payload delivery, and reduce off-target immune activation. This engineering approach facilitates the creation of "designer cytokines" with optimized therapeutic windows for complex disease indications.
Fig.1 Using photocaged tyrosines and UV light to control IL-24/IL-20R2 complex formation. (Pham, P. N., et al., 2023)
Our Services
Powered by a proprietary GCEngine platform, we offer integrated services for developing engineered cytokine therapeutics. This includes the identification and validation of novel orthogonal aaRS/tRNA pairs for diverse ncAA incorporation, followed by the design, expression, and functional characterization of ncAA-modified cytokines. Clients receive tailored cytokine engineering solutions encompassing function-driven design, in vitro validation, and in vivo applications, and scalable production support.
Customized Solutions for ncAA Incorporated Cytokine Engineering
To achieve improved therapeutic specificity, cytokine variants can be engineered to preferentially expand regulatory or tolerogenic cell populations, such as Tregs, while minimizing activation of effector cells. Strategic ncAA incorporation allows for the introduction of conditionally activated mechanisms, including tissue/cell-restricted signaling or signaling bias, thereby separating desirable anti-inflammatory effects from adverse pro-inflammatory responses.
- Orthogonal aaRS/tRNA Pair Development
High-throughput screening and systematic optimization of orthogonal aaRS/tRNA pairs to achieve high fidelity and efficiency for site-specific ncAA incorporation.
- Functional Cytokine Design & Engineering
Rational design or library-based approaches to introduce ncAAs for PEGylation, glycosylation mimicry, crosslinking, fluorophore attachment, or other functional handles.
- In Vitro Validation & Characterization
Comprehensive analysis of ncAA-incorporated cytokines regarding expression, purity, stability, and receptor binding affinity using advanced biophysical and cell-based assays.
- Functionality Testing
Evaluation of engineered cytokine signaling, potency, selectivity, and immunogenicity in relevant cellular models and preclinical animal systems, to characterize function and safety profiles.
Disease Area-Specific Services for ncAA Incorporated Cytokine Engineering
The platform enables engineering of cytokine therapies for oncology by leveraging site-specific ncAA incorporation to address challenges. This includes creating homogeneous, tumor-targeted immunocytokines with improved localization; developing conditionally activated "pro-cytokine" prodrugs to reduce systemic toxicity; and enabling precise functionalization of cytokines for arming adoptive cell therapies. Incorporation of bioorthogonal handles or crosslinking moieties supports the development of more effective and safer immuno-oncologic agents, from investigating novel receptor engagements to constructing multi-specific therapeutic conjugates.
For autoimmune and inflammatory diseases, services focus on redesigning cytokines for precise immune modulation. This involves engineering cytokine variants with site-specific modifications, such as controlled PEGylation to improve pharmacokinetics or cleavable masking groups for context-dependent activity to achieve localized effects primarily at disease sites. The strategy aims to create receptor-biased or conditionally activated therapeutics that attenuate pathogenic signaling while preserving protective functions, potentially enhancing efficacy and reducing off-target effects associated with broad immunosuppression.
Contact Us
Combining the advanced GCEngine platform with expertise in cytokine biology, we support the development of precise, potent, and novel cytokine therapeutics with streamlined workflows. Our integrated service model covers development from concept to preclinical candidate, offering partners a collaborative pathway to next-generation biologics. For custom project inquiries or to discuss potential collaborations, please contact us.
Reference
- Pham, Phuong Ngoc et al. "Regulation of IL-24/IL-20R2 complex formation using photocaged tyrosines and UV light." Frontiers in molecular biosciences 10 (2023): 1214235.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
